In this episode, Charles interviews Nikolaus Trede, the SVP Clinical Development in Century Therapeutics, an innovative biotechnology company that is building an industry leading allogeneic iPSC-derived cell therapy platform. He shares his journey from academia to industry, offering unique experience into the ever-changing world of cell therapies.
Here's what you're in for:
- What is unique about Century Therapeutics?
- How to build the most successful and the best functioning clinical development teams, practices, and operations?
- Why does differentiation often get lost, and how can developers or executives recognize signals that their differentiation strategy may be off?
- Why is dosing so contentious, especially in phases two and three? Why do teams often get it wrong?
- How do you approach the right selection process to build trust with the team and to avoid issues down the line?
- How did a negative result of the trial influence how you approach now your trial designs and your development?
- What is under communication? over communication?
- How can you reduce under communication so people do actually give as much as the most relevant information as possible?
- What is the secret to building a terrible team and culture?
Watch episodes here
- Apple Podcast: https://podcasts.apple.com/us/podcast/nikolaus-trede-svp-clinical-development-in-century/id1736051162?i=1000676681012
- Spotify: https://open.spotify.com/episode/1nI7aBVdkinLQnFOY5MuMB?si=01ea35820c2c47c7
About Nikolaus Trede
- A physician-scientist specializing in immunology and pediatric hematology/oncology. With a PhD in immunology and 15 years of clinical experience at institutions like Harvard Medical School and the University of Utah,
- He bridges basic science and patient care. Dr. Trede has led academic research labs and industry teams, designing and supervising clinical trials for innovative cancer treatments.
- His work spans from chronic myelogenous leukemia studies to current CAR T cell trials in hematologic malignancies at JUNO/Celgene, demonstrating his expertise in translating scientific concepts into clinical applications.
Connect with Nikolaus Trede: https://www.linkedin.com/in/nikolaus-trede/
About Century Therapeutics:
- The company specializes in allogeneic, induced pluripotent stem cell (iPSC)-derived natural killer (NK) and T cell therapies, which are designed to be more effective and accessible than traditional treatments.
- Century Therapeutics presented interim results from its Phase 1 ELiPSE-1 study, showing a manageable safety profile for CNTY-101 with no observed dose-limiting toxicities (DLTs).
- Century Therapeutics has engaged in significant partnerships, including a collaboration with Bristol Myers Squibb to develop and commercialize iPSC-derived NK and T cell programs for hematologic malignancies and solid tumors.
Website: https://www.centurytx.com/
Pipeline: https://www.centurytx.com/pipeline/
About me
My name is Charles Spence and I lead Discera. After many years working in the life-science recruitment world, I decided to work for myself. Before doing recruitment I graduated with a biomedical degree, have worked in hospitals (including translation work in Seoul, South Korea), and also spent a year working in diabetes research in Stockholm. After doing research and travel, a career in business and science felt the most appropriate.
In 2023, I decided to launch his firm - Discera Search. A firm committed to solving the biggest talent needs of early clinical stage SME biotechs on the East Coast and DACH.
Connect with me:
LinkedIn:https://www.linkedin.com/in/charles-spence-clinical/
Website: https://www.discera-search.com/
